Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 22, 2022

Primary Completion Date

December 20, 2022

Study Completion Date

December 20, 2022

Conditions
Charcot-Marie-Tooth Disease, Type IA
Interventions
DRUG

EN001

"EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group A (Low dose): 5.0x10\^5 cells/kg"

DRUG

EN001

"EN001 intravenously (IV) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A Dosage for each group is as follows.~Dose group B (High dose): 2.5x10\^6 cells/kg"

Trial Locations (1)

Unknown

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ENCell

INDUSTRY

NCT05333406 - Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A | Biotech Hunter | Biotech Hunter